Kyverna Therapeutics Inc. (NASDAQ:KYTX) Stock Price Settled at $22.52: What’s Resulting?

Wells Fargo raised the price target for the Kyverna Therapeutics Inc. (NASDAQ:KYTX) stock to “an Overweight”. The rating was released on March 04, 2024, according to finviz. The research report from Leerink Partners has initiated the stock to Outperform, with a price target set at $48. The stock was initiated by JP Morgan, who disclosed in a research note on March 04, 2024, to Overweight and set the price objective to $39.

The latest trade, Performances and Moving Averages give us the following Picture

The firm’s stock price fluctuated -12.44% within the last five trades and -17.11% within the last 30 trades, which was a significant change from the beginning of this year. KYTX stock is trading at a margin of -17.52%, -19.28% and -19.28% apart from the 20-Day, 50-Day and 200-Day Simple Moving Average prices.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

As of the close of trading, KYTX deals in the Healthcare domain. The stock is trading -35.77 percent below its 52-week high and -2.60 percent above its 52-week low. For example, looking both at the price and the high and low measurements of 52 weeks will give you a clearer picture of the direction the price is heading. The firm’s Weighted Alpha is null. A positive weighted alpha indicates the firm has done well over the course of the year, whereas one below 0 indicates that the firm has done poorly.

What Does Kyverna Therapeutics Inc.’s Profitability and Valuation Ratios Tell Us About the Stock?

The stock’s market cap achieved a total value of $970.61 million as of the last trading session. Market capitalization is the total value of all outstanding shares of a corporation and it is used to measure a company’s market value.

Is Insider Trading a Real Thing?

Almost all investors and traders prefer to invest in shares controlled by the management of a corporation as a management company will be more likely to run the business itself and to never conduct things against the management’s desires and will always try to do what is best for their shareholders. Currently, 58.75 percent of Kyverna Therapeutics Inc. shares are owned by insiders, and 3.25 percent are held by financial institutions. GILEAD SCIENCES, INC., the 10% Owner at Kyverna Therapeutics Inc. (KYTX) has bought 910,000 shares of firm on Feb 12 ’24 at a price of $22.00 against the total amount of $20.02 million. In another inside trade, Northpond Ventures III GP, LLC, Former 10% Owner of Kyverna Therapeutics Inc. (NASDAQ:KYTX) bought 450,000 shares of the firm on Feb 12 ’24 for a total worth of $9.9 million at a price of $22.00. An inside trade which took place on Feb 12 ’24, 10% Owner of Kyverna Therapeutics Inc. Bain Capital Life Sciences Inv bought 450,000 shares of firm against total price of $9.9 million at the cost of $22.00 per share.

Most Popular

Related Posts